Idarucizumab: What Should We Know?
| Autor: | Michele Gesualdo, Giacinto Calculli, Anna Maria Cortese, Annapaola Zito, Fiorella De Vito, Rossella Carbonara, Annagrazia Cecere, Francesca Cortese, Santa Carbonara, Marco Matteo Ciccone |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Idarucizumab Clinical Biochemistry Drug Evaluation Preclinical Postmarketing surveillance Hemorrhage Cochrane Library Antibodies Monoclonal Humanized Anticoagulant activity Antibodies Antithrombins Dabigatran Emergency surgery Monoclonal Drug Discovery medicine Animals Humans Intensive care medicine Humanized Pharmacology Clinical Trials as Topic business.industry Bleeding Anticogulant drugs Preclinical Antidote Clinical Practice Humanized Monoclonal Antibody Fragment Drug Evaluation Molecular Medicine business medicine.drug |
| Zdroj: | Current drug targets. 19(1) |
| ISSN: | 1873-5592 |
| Popis: | BACKGROUND Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis. Moreover, it can also be applied to reverse the dabigatran anticoagulant activity in emergency surgery or in other invasive procedure at high risk of bleeding. OBJECTIVE In this study, we discuss idarucizumab in light of the available literature data by conducting extensive research in the PubMed, EMBASE and Cochrane Library on the topic, using idarucizumab, dabigatran and their combinations as Mesh terms, and focusing on high impact investigations. RESULTS Several studies have demonstrated the capacity of idarucizumab to reverse laboratory measures of dabigatran-associated coagulopathy, however its efficacy and safety in real world patients are still not very clear because of the scarcity of available data which should be assessed with an extensive post market surveillance. CONCLUSION The introduction of idarucizumab as dabigatran antidote in clinical practice represents a useful tool for clinicians. The possibility to rapidly restore the anticoagulation activity of dabigatran makes its use simpler and more manageable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|